Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus

Kadmon Hlds

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.

Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock

French drugmaker Sanofi is buying Kadmon, the U.S. biopharmaceutical company, for a total equity value of $1.9 billion.

Kadmon Stock Soars as Sanofi Buys U.S. Biotech for $1.9 Billion

Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another billion-dollar deal. Sanofi-Kadmon Deal Terms: Sanofi announced Wednesday it has agreed to acquire New York-based biopharma Kadmon Holdings, Inc. (NASDAQ: KDMN) in a $1.9 billion all-cash deal.

Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know

French pharmaceutical major Sanofi SA said Wednesday that it has entered into a definitive agreement to acquire U.S.-based biopharmaceutical company Kadmon Holdings Inc.

Sanofi to acquire U.S. biopharmaceutical group Kadmon in $1.9 billion deal

French drugmaker Sanofi SA has agreed to buy U.S. biopharmaceutical company Kadmon Holdings Inc in a $1.9 billion deal, the companies said on Wednesday.

France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 billion deal

Amazon

Aspen Technology Inc

Alibaba

Bayer AG

Baidu

British American Tobacco

Anheuser-Busch InBev

Campbell Soup

Enterprise Products Partners

GlaxoSmithKline

Imperial Brands PLC

Intel

Kellogg

Lockheed Martin

Merck

Polaris

Reckitt Benckiser Group PLC

Roche Holding AG

Tencent Holdings Limited

Western Union

Yum China Hlds

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The September 2021 Heat Map

Ascendis Pharma

Cara Therapeutics

Jazz Pharmaceuticals

Sesen Bio Inc.

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – a measure of innovation in the biopharma sector – numbered four for the month, taking the total for the year to 36, two less than relative to the same period in 2020.

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

Regeneron Pharmaceuticals

Sanofi (SNY) and Regeneron (REGN)'s Dupixent meet all primary and secondary endpoints in phase III study to treat children aged six months to five years with moderate-to-severe atopic dermatitis.

Sanofi (SNY)/Regeneron's Dupixent Meets Eczema Study Goal

Axsome Therapeutics

AstraZeneca

Nasdaq

Novavax

Pieris Pharma

Cassava Sciences Inc

Seagen

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

Which Biotech Stock Will Shock the Market in 2022?

Eli Lilly

Novo Nordisk

House Energy & Commerce Committee leaders sent three letters to execs at Eli Lilly And Co (NYSE: LLY), Sanofi SA (NASDAQ: SNY), and Novo Nordisk A/S (NYSE: NVO), raising concerns that despite their supposed concern over the past two years with the price of insulin, the price still remains "unacceptably high." Committee chair Frank Pallone (D-NJ) and subcommittee chair Diana DeGette (D-CO) note in all three letters that the price of insulin in the U.S. is more than 10 times that of 33 other countries.

House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On 'Unacceptably High' Insulin Prices

Telesis Bio Inc

Before the $3.2 billion acquisition of mRNA player Translate Bio Inc (NASDAQ: TBIO) earlier this month, Sanofi SA (NASDAQ: SNY) expressed interest in selling off around 25% of its shares in the company, which it had been working with since 2018. Translate Bio filed SEC document to give an inside look at how the buyout negotiations played out.

Inside Sanofi's $3.2B Translate Bio Buyout

Bristol-Myers

Mirati Therapeutics

The next few months are critical for these biotech stocks which could witness a massive increase in their stock prices this year The post 3 Best Biotech Stocks To Buy for Upcoming Catalysts appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar

3 Best Biotech Stocks To Buy for Upcoming Catalysts

The FDA gives approval to Sanofi's (SNY) Nexviazyme (avalglucosidase alfa) for treating late-onset Pompe disease.

Sanofi (SNY) Pompe Disease Drug Receives FDA's Approval

The Phase 3 trial of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small-cell lung cancer (NSCLC).  These data are planned to form the basis of regulatory submissions in the U.S. and European Union.

Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer

Pharmaceutical company Sanofi remains under pressure to launch new drugs and overcome setbacks in the COVID-19 vaccine race, despite a $3.2 billion deal to tighten its grip on promising mRNA technology.

Analysis-Sanofi's COVID-19 vaccine setback, drug pipeline cast long shadow

Sanofi has agreed to acquire U.S. biotech company Translate Bio to gain exposure in the mRNA vaccine space.

Sanofi to Buy mRNA Developer: ETFs in Focus

Chevron

Leggett & Platt

People's United Financial

Red Electrica Corp SA

Swiss Re AG

AT&T

Unilever

Walgreens

Exxon Mobil

Kiplinger "insights for investors" online first offered a list of 91 "Top Dividend Stocks From Around The World" 7/13/20. Two recent Kiplinger articles provided 102 Top Dividend Stocks on Earth list 7/1/21. 39 European “Dividend Aristocrats” showed 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats showed 25 years of increases for U.S. companies.

The 102 Most Reliable Dividends On Earth For August

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Translate Bio (NasdaqGS: TBIO) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Translate will receive only $38.00 in cash for each share of Translate that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whe

TRANSLATE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Translate Bio - TBIO

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Translate Bio, Inc. ("Translate" or the "Company") (NASDAQ: TBIO) in connection with the proposed acquisition of the Company by Sanofi ("Sanofi") (NASDAQ: SNY) via a tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $38.00 in cash for each share of Translate common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Translate Bio, Inc.

Biotech stocks surge after big news & bullish analyst ratings. The post Hot Biotech Stocks To Watch After Sanofi's Acquisition Of Translate Bio appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Stocks To Watch After Sanofi's Acquisition Of Translate Bio

The deal represents a 56% premium to Translate Bio's volume-weighted average price per share over the past 60 days.

Translate Bio soars 30% after Sanofi agrees to buy the mRNA company for $3.2 billion

Shares of Translate Bio Inc. soared 29.8% in premarket trading on Tuesday after Sanofi said it will spend $3.2 billion to buy the developer of messenger RNA (mRNA) technologies. The U.S.-listed shares of Sanofi were down 0.1% in premarket trade.

Sanofi to buy mRNA developer for $3.2 billion

Sanofi SA (NASDAQ: SNY) has announced it is buying Translate Bio (NASDAQ: TBIO) in a deal valued at about $3.2 billion. These are the details.

Why Sanofi (SNY) Is Buying Translate Bio (TBIO) For $3.2 Billion

A year after paying Translate Bio Inc (NASDAQ: TBIO) a whopping $425 million to develop mRNA vaccines for infectious diseases, including COVID-19, Sanofi SA (NASDAQ: SNY) has announced a $3.2 billion buyout for Translate Bio. Sanofi will pay $38 in cash for each of Translate Bio's shares, a 30% premium to Monday's closing price of $29.15.

News for Sanofi Stock (SNY)